EUCTR2017-000353-39-IT进行中（未招募）1 期
The CONFRONT Phase I – II Trial: ACtivatiON oF immune RespONse in paTients with R-M Head and Neck Cancer. Multimodality immunotherapy with Avelumab, short course radiotherapy and Cyclophosphamide in Head and Neck cancer. - CONFRONT
G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST0 个研究点目标入组 71 人开始时间: 2018年4月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Be willing and able to provide written informed consent for the trial. The subject may also provide consent for the translational study.
- •2.Be = 18 years of age on day of signing informed consent.
- •3.ECOG Performance Status 0-2.
- •4.Have histologically or cytologically-confirmed recurrent or metastatic (disseminated) head and neck squamous cell carcinoma
- •5.Have a disease progression after treatment with at least one line of therapy including at least Cisplatin, Fluorouracil and Cetuximab for recurrent (disease not amenable to curative treatment)/metastatic disease.
- •6.Measurable disease by RECIST criteria.
- •7.At least one metastatic site suitable for irradiation
- •8.Life expectancy > 3 months.
- •9.Adequate bone marrow function: neutrophils = 1.5 x 109/L, platelets = 100 x 109/L, hemoglobin =9 g/dL.
- •10.Adequate liver function: AST and ALT levels = 2.5 × ULN; bilirubin = 1.5 x ULN.
- •11.Adequate renal function: creatinine clearance = 30 mL/min (Cockroft-Gault).
- •12.Fertil men must be using adequate contraceptive measures throughout the study period if their partner are women of childbearing potential.
- •13.If of childbearing potential, women must use effective contraceptive method (Pearl Index < 1; e.g. oral contraceptive (pill), hormone spiral, hormone implant, transdermal patch, a combination of two barrier methods (condom and diaphragm), sterilisation, sexual abstinence) for the study duration and for at least 30 days after last avelumab treatment administration if the risk of conception exists.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 21
排除标准
- •1.History of malignant disease (with the exception of non-melanoma skin tumours and/or in situ cervical cancer) in the preceding five years.
- •2.Brain metastases.
- •3.Autoimmune disorders. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
- •4.Allergic disorders.
- •5.Cyclophosphamide treatment contraindications:
- •a.Cystitis.
- •b.Urinary Obstruction.
- •c.Inadequate bone marrow function: WBC <2900 mm3 and/or HCT <30% and/or platelets count <90000 mm3.
- •d.Active infections.
- •e.Pregnancy or breast feeding.
- •6.Prior treatment with inhibitors of the PD-L1 – PD – 1 axis or inhibitors of CTLA-4 (immune check point inhibitors)
- •7.Previous HBV or HCV infections.
- •8.Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- •9.Any active infection requiring specific treatment (Antibiotics, antimicotic, antiviral).
- •10.Radiotherapy within 6 weeks before enrolment
- •11.Other non-malignant uncontrolled systemic diseases or social conditions that would preclude trial entry in the opinion of the investigator.
- •12.Prior organ transplantation including allogenic stem-cell transplantation.
- •13.Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
- •14.Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade = 2, or other Grade = 2 not constituting a safety risk based on investigator’s judgment are acceptable.
- •15.Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •16.Avelumab treatment contraindications:
- •a.Hypersensitivity to the active ingredient or to any excipient.
- •b.Inadequate bone marrow function: WBC <2900 mm3 and/or HCT <30% and/or platelets count <90000 mm3.
- •c.Uncontrolled serous effusions (pleural, pericardic or peritoneal)
- •d.Blood Pressure <60 mmHg.
- •e.Pregnancy or breast feeding.
- •f.Active infections.
- •Known history of testing positive for HIV or known acquired immunodeficiency syndrome.
- •g.Brain metastases.
- •h.Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
- •17.Participation to other concomitant experimental study.
研究者
相似试验
进行中（未招募）
1 期
Phase I/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients with Retinopathy of PrematurityRetinopathy of PrematurityJPRN-jRCT2071200047Arima Mitsuru24
已完成
不适用
A PHASE II PROSPECTIVE TRIAL CORRELATING THE PROGRESSION FREE SURVIVAL CYP2D6 WITH ACTIVITY IN PATIENTS WITH METASTATIC BREAST CANCER TREATED WITH SINGLE AGENT TAMOXIFE-C61 Malignant neoplasm of prostateMalignant neoplasm of prostateC61PER-114-10EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG), GRUPO DE ESTUDIOS CLINICOS ONCOLOGICO DEL PERU GECOPERU,37
进行中（未招募）
不适用
TRIAL PHASE II MULTICENTER FOR CANCER PATIENTS DIAGNOSED WITH OSTEOSARCOMA WITH METASTASIS WHO HAVE ALREADY BEEN TREATED PREVIOUSLYEUCTR2012-001106-26-ESJAVIER MARTÍN BROTO
进行中（未招募）
2 期
A Multi Centre, Pilot Phase II Trial Assessing The Efficacy And Safety Of Bevacizumab + Gemcitabine + Carboplatin As First Line Treatment For Patients Diagnosed With Triple Negative Metastatic Breast Cancer.CTRI/2010/091/001135Roche Products India Pvt Ltd44
进行中（未招募）
不适用
A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients with Essential Thrombocythemia who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or who Refuse Standard TherapyMedDRA version: 16.0Level: PTClassification code 10015493Term: Essential thrombocythaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Essential thrombocythemiaEUCTR2010-023076-10-DEGeron Corporation40